Excelra Launches GOBIOM+, an Intuitive Avatar of Its Flagship Biomarker Intelligence Platform

Excelra Launches GOBIOM+, an Intuitive Avatar of Its Flagship Biomarker Intelligence Platform

PR Newswire

HYDERABAD, India, April 8, 2019

HYDERABAD, India, April 8, 2019 /PRNewswire/ -- Excelra (www.excelra.com), a leading data and analytics company, announced the successful release of GOBIOM+ (Global Online Biomarker Database), the most comprehensive and high-quality biomarker intelligence platform. GOBIOM+ is geared to support quick, reliable and data-driven decision making in translational drug development.

Excelra launches GOBIOM+

To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/8522851-excelra-launches-intuitive-avatar/

GOBIOM+ is a user-centric revamp designed to go from data to insights in an instant. The new platform is built on a responsive microservice oriented architecture and powered by a state-of-the-art technology stack — the result: enhanced functionality that connects biomarker data with analytics and an intuitive user experience.

Some of the novel functionalities include:

The User Interface is designed to help the user interact seamlessly with the data to quickly find the specific answers to their questions without the distraction of irrelevant information and cumbersome data cleanup. Some of the highlights of the interface include:

Furthermore, the platform provides seamless connectivity with semantic tagging and integrated API services that enables the platform to communicate with other backend systems. A subscription also includes custom curation and report generation services. 

"GOBIOM+ is our flagship database product that scientists and researchers use in understanding the biomarker and disease landscape. It is a powerful solutioning platform addressing critical questions in the R&D cycle from drug discovery to clinical development. We constantly strive to ensure our clients have the best experience and this philosophy deeply informs our revamp of the product," said Dr. Jesintha Maniraja, Director Biology Services who is also the force behind the new GOBIOM+.

Clients leverage GOBIOM+ to:

About GOBIOM+
GOBIOM+ Biomarker Database is a comprehensive biomarker database that provides information on Proteomic, Genomic, Biochemical, Imaging, Metabolite, Clinical Scoring scales and Cellular biomarkers for 18 different therapeutic areas, covering ~2900 therapeutic indications with its reported utilities like diagnosis, prognosis, monitoring disease progression, treatment response, surrogate, efficacy and toxicity. Information in GOBIOM+ biomarker database gathered from diverse sources, includes clinical trials, scientific conferences, regulatory-approved documents and literature databases.

About Excelra:
Excelra's data and analytics solutions empower innovation in life sciences across the value chain from molecule to market. The Excelra Edge comes from a seamless amalgamation of data, deep domain expertise and data science. The company's multifaceted team helps harmonize large volumes of disparate unstructured data; analyze data using cutting-edge AI/ML technologies; and galvanize data-driven decisions to unlock operational efficiencies and accelerate drug development. Being an end-to-end solution provider, Excelra helps break down silos, integrate data and analytics across Omics, Clinical Trials, and RWE to uncover novel insights and opportunities. Over the last 17 years, Excelra has been the preferred data and analytics partner to over 150 clients including 15 of the top 20 large Pharma companies. To Explore the Excelra Edge - visit www.excelra.com

Excelra is hosting a series of webinars to demonstrate how clients can leverage the data from GOBIOM+ in the R&D for various indications. One can write to marcom@excelra.com to register.

Excelra is headquartered in Hyderabad with offices in Boston, Utrecht, and Bangalore.

(Photo: https://mma.prnewswire.com/media/848021/GOBIOM.jpg)

For any media query, please reach us at:
Urvi Mehta
Excelra
urvi.mehta@excelra.com 
M: +91-96526-72200
www.excelra.com

 

Voltar noticias em Inglês